Life sciences company Revvity (NYSE:RVTY)
will be reporting results tomorrow before market hours. Here’s what investors should know.
Revvity met analysts’ revenue expectations last quarter, reporting revenues of $729.4 million, up 4.8% year on year. It was a slower quarter for the company, with full-year revenue guidance slightly missing analysts’ expectations.
This quarter, analysts are expecting Revvity’s revenue to grow 1.6% year on year to $660.6 million, a reversal from the 3.7% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.95 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Revvity has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Revvity’s peers in the research tools & consumables segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Danaher posted flat year-on-year revenue, beating analysts’ expectations by 2.7%, and Thermo Fisher reported flat revenue, topping estimates by 1.3%. Danaher traded up 6.2% following the results while Thermo Fisher was down 1.8%.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the research tools & consumables stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.6% on average over the last month. Revvity is down 6.4% during the same time and is heading into earnings with an average analyst price target of $132.55 (compared to the current share price of $99).
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.